Vladimir Kushnarev

@deniswirtz I remember trying to create reconstructions using 3D Histech software in 2022. Have you tried making the first five slides (or, in theory, fewer) and then five at the end for reconstruction? I'd love to hear you and your presentation.

@oncopathologist Yes and yes

I will be giving talks at UC San Diego (Dept Bioengineering) and Sanford Burnham Prebys Institute this coming Friday and the following Tuesday in La Jolla. I will talk about 3D mapping of solid tumors and new CAR T therapies to resolve them. Hope to see you there.

Grateful to @PavlosMsaouel and his team for an insightful collaboration and the chance to work on this study published Cell Reports Medicine: cell.com/cell-reports-m…

Our new work in Scientific Reports! We show how RNA-seq and IHC together improve tumor biomarker interpretation, defining RNA cut-offs for ER, HER2, PD-L1, Ki-67 and more. A step toward integrating transcriptomics into pathology. 🔗 nature.com/articles/s4159… #oncology #biomarkers

Our new paper in JMD introduces the Morphological Bone Score - a simple 5-point H&E checklist to predict sequencing success before you send the sample. A quick look down the scope can save thousands and prevent wasting a precious sample. doi.org/10.1016/j.jmol…

@Nature_NPJ #npjBCancer

We need a stable, reproducible way to classify breast cancers that captures the full continuum of HER2 status, refines the distinction between luminal subtypes, and ensures we match each patient with the best possible treatment. Check our new article! doi.org/10.1038/s41523…

Our latest #MsaouelLab report dissects an extreme & unexpected phenotypic plasticity by #RenalMedullaryCarcinoma during #EZH2 inhibition. Much remains to be understood about what triggers and how to counteract such “mimicry”/transdifferentiation mechanisms across cancers. #endRMC

Excited to share our journey at UCAP 2024 in Baltimore, showcasing our digital pathology and machine learning innovations. Proud to work alongside our amazing team and CSO Joe Lennerz. For more on how we’re changing healthcare, visit our site: bostongene.com #USCAP2024

Dr. Mouabbi presented results of our work at SABCS 2023 regarding ILC Breast Cancer! Using new imaging modalities and multiplex immunohistochemistry as a novel way for biomarker search. #sabcs2023

Clear cell sarcoma - malignant melanoma? Female, 40 y.o, axillary lymph node. Spindled to epithelioid tumor, arranged in sheets and variably sized nests within a lymph node. SOX10 S100 positive, MCK(AE1/AE3) negative. After NGS testing we found EWSR1-ATF translocation.

Excellent representation of comparison between the level of HER2 expression (classified as HER2-0, HER2-low, or HER2-positive) in the needle biopsy and the corresponding resection specimen from Ximena Baez-Navarro and co-authors doi.org/10.1016/j.modp…

New case - Intrahepatic cholangiocarcinoma with CREBBP and TNFRSF1A mut. It was challenging ddx with HCC based on H&E. IHC with Hepar, Arg1, CK19, glipican3, Nestin can help with right diagnosis.

Trend article from Modern pathology (it is now Elsevier) sciencedirect.com/science/articl… - fair agreement among pathologists (range 0.45 to 0.55). And my recent case - Signet-ring cell pattern in GE adenocarcinoma. PD-L1 staining shows CPS 10.

Got new case: myxofibrosarcoma of left thigh. It has prominent elongated, thin-walled blood vessels with a perivascular condensation of tumour cells. After NGS profiling we found CNND1 amplification with low TMB and MSS. Angiogenesis gene signature is high. #PathTwitter

Personally I prefer digital slides to the microscope. And I am a lot faster too! @RunjanChetty

All WHO blue books are 5th edition🥳

My first poster in USCAP 2023. I hope to publish a manuscript soon:)

Got wonderful NTRK3 translocated case of metastatic anal adenocarcinoma with neuroendocrine differentiation. No any TP53 and RB1 mutations.

Nice photos of ccRCC g4 with rhabdoid features and mitosis. #ccrcc #pathology #kidneycancer